Ausman J I, Diaz F G, Malik G M, Fielding A S, Son C S
Surg Neurol. 1985 Dec;24(6):625-35. doi: 10.1016/0090-3019(85)90120-x.
The overall morbidity and mortality from aneurysmal subarachnoid hemorrhage have not changed significantly over the past 30 years in spite of great progress in surgical technology and diagnostic capabilities. Most series report major morbidity and mortality figures of approximately 60%. The reason for the currently poor prognosis is due, in part, to the sometimes devastating effect of the initial hemorrhage over which we have no control. Another reason for our inability to improve these dismal statistics may be that the currently accepted treatment regimens have proven to be ineffective. Eighteen misconceptions or "myths" surrounding the treatment of aneurysmal subarachnoid hemorrhage have been identified as factors that have largely determined the currently accepted, ineffective treatment protocols, and these are discussed.
尽管在外科技术和诊断能力方面取得了巨大进展，但在过去30年中，动脉瘤性蛛网膜下腔出血的总体发病率和死亡率并未显著改变。大多数系列报道的主要发病率和死亡率数字约为60%。目前预后不佳的部分原因在于初始出血有时会产生毁灭性影响，而对此我们无法控制。我们无法改善这些令人沮丧的统计数据的另一个原因可能是，目前公认的治疗方案已被证明无效。围绕动脉瘤性蛛网膜下腔出血治疗存在的18个误解或“误区”已被确定为在很大程度上决定了目前公认的无效治疗方案的因素，并将对这些误解进行讨论。
